首页> 外文期刊>Vaccine >Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain.
【24h】

Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain.

机译:新型的减毒的传染性支气管炎病毒疫苗候选株的鉴定,该候选疫苗来自韩国的肾致病性毒株。

获取原文
获取原文并翻译 | 示例
           

摘要

A nephropathogenic K2/01 strain of infectious bronchitis virus (IBV) was attenuated by 170 serial passages in embryonated chicken eggs for possible use as a future IBV vaccine strain. High-growth properties and narrow tissue tropisms (limited replication in respiratory tracts) were achieved by the adaptation process. Unlike the parent strain, the attenuated strain (K2p170) was safe in day-old specific-pathogen-free chicks since replication of the virus did not induce mortality and nephritis, and rarely induced histological changes in the trachea and kidney after intraocular administration. In day-old broilers, even though coarse spray administration of K2p170 induced clinical signs, ciliostasis, and histopathological lesions in the trachea and the kidney, they were all comparable to birds vaccinated with commercial H120 vaccine. Despite restriction of viral replication in the respiratory tract, K2p170 elicited the production of antiserum with a neutralization index of 4.5. K2p170 provided almost complete protection against both two distinct subgroups of Korean nephropathogenic strain (KM91-like and QX-like subgroup). Furthermore, K2p170 provided significantly greater cross-protection against two heterologous strains (Massachusetts and Korean respiratory strain) than those conferred by the commercial H120 vaccine. K2p170 also had no virulence reversion after five back passages in chickens. In conclusion, K2p170 exhibits a fine balance between attenuation and immunogenicity, possesses cross-protective efficacy, and merits further investigation as a potential live vaccine as an alternative means of protection against the recently emergent nephropathogenic IBV infection in many Eurasian countries.
机译:传染性支气管炎病毒(IBV)的肾致病性K2 / 01株在胚胎鸡蛋中经170次连续传代而减毒,可能用作将来的IBV疫苗株。通过适应过程实现了高生长特性和狭窄的组织嗜性(在呼吸道中有限的复制)。与亲本菌株不同,减毒菌株(K2p170)在日龄无特定病原体的雏鸡中是安全的,因为该病毒的复制不会引起死亡率和肾炎,并且在眼内给药后很少引起气管和肾脏的组织学改变。在日龄的肉鸡中,即使粗喷K2p170引起气管和肾脏的临床体征,纤毛停滞和组织病理学损害,它们都可与接种商业H120疫苗的禽类媲美。尽管在呼吸道中病毒复制受到限制,但K2p170仍以4.5的中和指数引发了抗血清的产生。 K2p170提供了针对韩国肾致病菌株的两个不同亚组(KM91样和QX样亚组)的几乎完全保护。此外,K2p170对两种异源菌株(马萨诸塞州和韩国呼吸道菌株)的交叉保护作用比商业H120疫苗所赋予的交叉保护要大得多。在鸡中传回五次后,K2p170也没有毒性逆转。总之,K2p170在减毒和免疫原性之间显示出良好的平衡,具有交叉保护作用,值得作为进一步的研究作为一种潜在的活疫苗,作为在许多欧亚国家抵抗新近出现的肾致病性IBV感染的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号